Pegargiminase (also known as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1).[1][2][3][4] It is a recombinant form of the enzyme arginine deiminase cloned from the bacteria Mycoplasma hominus and synthesized in Escherichia coli. It has been pegylated to improve the half-life and reduce immunogenicity.[1]
| Clinical data | |
|---|---|
| Other names | ADI-PEG20 |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| ChEMBL | |
References
edit- ^ a b Feun L, Savaraj N (July 2006). "Pegylated arginine deiminase: a novel anticancer enzyme agent". Expert Opinion on Investigational Drugs. 15 (7): 815–22. doi:10.1517/13543784.15.7.815. PMC 3086545. PMID 16787144.
- ^ Kuo MT, Savaraj N, Feun LG (August 2010). "Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes". Oncotarget. 1 (4): 246–51. doi:10.18632/oncotarget.135. PMC 2998341. PMID 21152246.
- ^ Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E (November 2014). "The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials". Expert Opinion on Investigational Drugs. 23 (11): 1517–29. doi:10.1517/13543784.2014.934808. PMID 24965808.
- ^ Field GC, Pavlyk I, Szlosarek PW (February 2023). "Bench-to-Bedside Studies of Arginine Deprivation in Cancer". Molecules. 28 (5). Basel, Switzerland: 2150. doi:10.3390/molecules28052150. PMC 10005060. PMID 36903394.